Prime Medicine Posts $1.35 Loss Per Share for Full-Year 2025
PRME has more than doubled off its 52-week low of $1.11.
Summary
Prime Medicine reported a loss of $1.35 per share for the full fiscal year 2025. This financial update provides a key metric on the company's operational performance and cash utilization over the past year. While losses are common for clinical-stage biotechnology companies, the specific magnitude of the loss is material for investors assessing the company's financial runway and progress. Traders will now focus on the full earnings report for details on revenue, cash position, and any forward-looking guidance or pipeline updates to gauge future prospects.
At the time of this announcement, PRME was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $841.2M. The 52-week trading range was $1.11 to $6.94. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.